Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Active Not Recruiting3
Withdrawn1

Clinical Trials (4)

Showing 4 of 4 trials
NCT03784326Phase 2Active Not Recruiting

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

NCT03776487Phase 2Active Not Recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

NCT04929392Phase 2Active Not Recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

NCT05296005Phase 1Withdrawn

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Showing all 4 trials

Research Network

Activity Timeline